Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

J. Gao; Q. He; S. Subudhi; A. Aparicio; A. Zurita-Saavedra; D. H. Lee; C. Jimenez; M. Suarez-Almazor; P. Sharma

doi:10.1038/onc.2015.5

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

J. Gao, Q. He, S. Subudhi, A. Aparicio, A. Zurita-Saavedra, D. H. Lee, C. Jimenez, M. Suarez-Almazor, P. Sharma

Research output: Contribution to journal › Review article › peer-review

47 Scopus citations

Abstract

Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.

Original language	English (US)
Pages (from-to)	5411-5417
Number of pages	7
Journal	Oncogene
Volume	34
Issue number	43
DOIs	https://doi.org/10.1038/onc.2015.5
State	Published - Oct 1 2015

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/onc.2015.5

Cite this

@article{83be5d7c13d84873afe8ef861f9acc7f,

title = "Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience",

abstract = "Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.",

author = "J. Gao and Q. He and S. Subudhi and A. Aparicio and A. Zurita-Saavedra and Lee, {D. H.} and C. Jimenez and M. Suarez-Almazor and P. Sharma",

year = "2015",

month = oct,

day = "1",

doi = "10.1038/onc.2015.5",

language = "English (US)",

volume = "34",

pages = "5411--5417",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "43",

}

TY - JOUR

T1 - Review of immune-related adverse events in prostate cancer patients treated with ipilimumab

T2 - MD Anderson experience

AU - Gao, J.

AU - He, Q.

AU - Subudhi, S.

AU - Aparicio, A.

AU - Zurita-Saavedra, A.

AU - Lee, D. H.

AU - Jimenez, C.

AU - Suarez-Almazor, M.

AU - Sharma, P.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.

AB - Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.

UR - http://www.scopus.com/inward/record.url?scp=84945472104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945472104&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.5

DO - 10.1038/onc.2015.5

M3 - Review article

C2 - 25659583

AN - SCOPUS:84945472104

SN - 0950-9232

VL - 34

SP - 5411

EP - 5417

JO - Oncogene

JF - Oncogene

IS - 43

ER -

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this